Gavin Tan

LLB Law (Bristol)

Founding Director and Group Chief Executive Officer


Mr Gavin Tan is a founding director and CEO of the CellResearch Corporation Group of Companies. With an active interest in the life sciences sector, Mr Tan recognised the growth potential of the industry when in 2002, he invested and co-founded CellResearch Corporation. Mr Tan has been instrumental in charting the strategy and growth of CellResearch Corporation and its subsidiaries. Mr Tan has over 22 years of experience in Asian financial markets. For seven years prior to assuming his current role at CellResearch Corporation, Mr Tan was Head of Institutional Sales at NomuraSecurities Singapore Pte Ltd where he was responsible for directing and developing the firm’s institutional equity business in Singapore and Malaysia. Mr Tan has extensive experience in developing and marketing equities products as well as growing an international business.


Mr Tan holds executive directorships and non-executive directorships in several companies including Aglaia Family Office Pte Ltd, an Asian based diversified asset management company and multi-family office.


Phan Toan Thang


Founding Director and Group Chief Scientific Officer


Associate Professor and Principal Investigator of the Wound Healing and Stem Cell Research Group, Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore. 

Professor Phan is a founding director and CSO of CellResearch Corporation Group of Companies. A graduate of the Military Medical University, Hanoi, Vietnam in 1991, Prof. Phan Toan Thang has had a strong interest in wound healing since the earliest days of his medical and scientific career. His interest led him to hands-on experience during his four-year surgical residency in Hanoi at the National Institute of Burns and at the Army Hospital 103. Prof. Phan's commitment and excellence in laboratory research was proven when he spent two years at the prestigious Wound Healing Institute and Department of Dermatology in Oxford, England. 

He arrived in Singapore in 1997 to join the Department of Plastic Surgery at the Singapore General Hospital. In 1998, he met Mr Ivor Lim, and together they established the Skin Cell Research Group (currently Wound Healing and Stem Cell Research Group) focusing on skin and keloid scar biology. The Wound Healing and Stem Cell Research Group was the first group in the world to explore the role of epithelial-mesenchymal interactions in keloid pathogenesis, and is recognised today as one of the world leading groups in keloid and scar biology research. 

Prior to taking up his faculty position at the Department of Surgery, Yong Loo Lin School of Medicine and Faculty of Dentistry at the National University of Singapore, Prof. Phan completed two years of post-doctoral research at the Stanford University Children Surgical Research Laboratory. 

Prof. Phan is author of more than 80 publications in international peer-reviewed journals, two book chapters, has more than 35 granted patents and serves as a reviewer for prestigious international scientific journals as well as local and international research funding bodies. His recent innovative research work is the discovery of a novel source of stem cells from the umbilical cord lining membrane with translational potential for regenerative medicine, tissue engineering and cell-based therapy.



Ivor J Lim

Founding Director


Mr Lim is a Founding Director of CellResearch Corporation Group of Companies which is focused on the research and commercialisation of Umbilical Cord Lining membrane Stem Cells, a patented technology that he co-developed with Professor Phan.

He received his undergraduate professional training at Cambridge University, and postgraduate training in London.

In addition to directing the Skin Cell Research Group at the National University of Singapore where he has an academic affiliation, he has international collaborations for research, reviews grants both locally and internationally, and is a peer reviewer for local and international scientific and professional journals.



Abbas Hussain

Senior Advisor

Abbas Hussain has joined the Advisory Board of CellResearch Corporation as Senior Advisor in the last quarter of 2017. The former global head of GlaxoSmithKline will be utilising his expertise on pharmaceutical value chain to advise the board on market commercialisation of its key products. He will also help overlook the company’s research and development strategies, manufacturing processes, and regulatory measures.

Mr Hussain brings with him over 30 years of global pharmaceutical experience. Prior to his role at CellResearch Corporation, Mr. Hussain had spent eight years at GSK, first as head of its emerging markets and Asia Pacific region, and later head of Pharmaceuticals. Having spent over eight years at GSK, Mr Hussain has been credited with building one of the world’s biggest pharma business. CellResearchCorp is looking forward to an era of increased growth with Mr Hussain’s contribution.


Richard Davies

Senior Advisor

Richard Davies joined the Advisory Board of CellResearch Corporation as Senior Advisor in the middle of 2018. Richard brings over 27 years’ of experience in the global healthcare industry in roles that spanned business development, commercialisation and sales, invaluable assets in this growth phase of CellResearch.

Richard is currently Chairman of the Board at Alvotech, a pioneering biosimilars Company. He has previously served on the Boards of ZHOPL and Medicines Australia. Richard was most recently chief executive officer of BONESUPPORT AB where he successfully led the growth of the company through its initial public offering after gaining approval for a pivotal clinical study design with the FDA. Prior to this, he was chief commercial officer of Hospira for 4 years, where he was responsible for continued revenue growth of 12% per year, after which the company was acquired by Pfizer for $15 billion. For a decade before joining Hospira, Richard served in several leadership roles at Amgen Inc. where he oversaw the biotechnology company’s business expansion into Central and Eastern Europe, Australia, Asia and Latin America. Prior to Amgen, Richard held roles of increasing seniority at Eli Lilly for 13 years.


Dr Mitchel Goldman


CALECIM® Professional Medical Advisory Board


Dr. Mitchel Goldman has been appointed Chairman of the CALECIM® Professional Medical Advisory Board in mid-2017. CALECIM® Professional is a physician dispensed skincare brand that is a wholly owned entity of CellResearchCorp. CALECIM® Professional utilises CellResearchCorp’s key stem cell technology in its range of anti-aging products.

Dr Goldman, the San Diego-based and highly acclaimed skin rejuvenation expert will be collaborating with CALECIM® Professional on a variety of projects, including clinical trials and new product development. As the Co-Founder of SkinMedica, and author of numerous textbooks, publications and public lectures, Dr Goldman is considered the foremost expert in aesthetic therapy and rejuvenation. In his role as Chairman, Dr Goldman will co-develop CALECIM® technology, and further global education on stem cell technology in skincare.



Kirstin Liechty

Clinical Operations Consultant

Kirstin is an experienced Clinical Research Professional with over 19 years of experience in investigator initiated and phase I-IV US and global clinical trials. Having experience in academics, clinical research organizations, and the Biotech side of research, Kirstin’s primary focus is early phase clinical trials and first in human studies for cellular and biological therapies.  Kirstin has a long history of working in a cross functional environment to meet study deliverables and manage multiple timelines. Kirstin’s early career experience in basic research looking at the immunogenicity of mesenchymal stem cells has proven invaluable for a unique understanding of many aspects of the job of Clinical Operations and Project Management, especially data management and laboratory requirements.